TOP-5 Analyst Price Targets as of May 22, 2026
Reading Time: 3 minutes
Eli Lilly [US5324571083] Wolfe Research confirms Outperform rating with a price target of 1350 USD (30% upside potential) Eli Lilly has achieved a remarkable milestone with the new Phase 3 data on Retatrutide. The results show a weight loss of up to 28.3% after 80 weeks and over 30% after 104 weeks in subjects with higher BMI – figures that stand out even in the rapidly growing GLP-1 segment. Accompanying this, numerous cardiometabolic risk factors improved, highlighting the therapeutic breadth of the compound. Analysts at Wolfe Research emphasize...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
